CD268 in BCP-ALL

CD268 (BAFF-R, TNFRSF13C) is a significant marker for B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). Ancell clone ANC268.2 was used to phenotype patient samples.  Blocking the BAFF – BAFFR pathway may prove to be useful in treating BCP-ALL. 

“TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia.”G Fazio, G Cazzaniga, et al. (2017) BJH doi: 10.1111/bjh. 14794   PMID: 28573703

Relevant Ancell Products:

anti-CD268(BAFF-R) mAb

anti-CD257(BAFF) mAb

anti-CD269(BCMA) mAb

Recombinant CD268(BAFF-R)-muIg

Recombinant CD269(BCMA)-muIg

Recombinant CD257(BAFF)-muCD8